The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).
 
Zeynep Eroglu
Consulting or Advisory Role - Incyte; Natera; Pfizer; Regeneron; Replimune; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
 
James Moon
No Relationships to Disclose
 
Yana Najjar
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; InterVenn Biosciences; Mallinckrodt/Therakos; Merck; Pfizer
Speakers' Bureau - Immunocore; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer/EMD Serono (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Istari
 
Rupesh Kotecha
Honoraria - BrainLAB; Elekta; IBA; InSightec; Kazia Therapeutics; Novocure; ViewRay
Consulting or Advisory Role - Novocure; ViewRay
Speakers' Bureau - GT Medical Technologies (I); Novocure
Research Funding - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); BrainLAB (Inst); Cantex Pharmaceuticals, Inc. (Inst); Exelixis (Inst); GT Medical Technologies (Inst); IBA (Inst); Kazia Therapeutics (Inst); Medtronic (Inst); Novocure (Inst); ViewRay (Inst)
Travel, Accommodations, Expenses - BrainLAB; Elekta; Novocure; ViewRay
Other Relationship - GT Medical Technologies Data Safety Monitoring Board; InSightec Advisory Board; Plus Therapeutics Data Safety Monitoring Board
 
Michael Wu
No Relationships to Disclose
 
Vadim Spektor
No Relationships to Disclose
 
Nikhil Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics
 
Larissa Korde
No Relationships to Disclose
 
Elad Sharon
Consulting or Advisory Role - D.E. Shaw Research; Mallinckrodt/Therakos
 
Kenneth Grossmann
No Relationships to Disclose
 
John Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; AXIO Research; Boxer Capital; Bristol Myers Squibb; CytomX Therapeutics; DermTech; Engage Health Media; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lumira Capital Investment Management; Lytix Biopharma; Magnolia Innovation; Merck; Mural Oncology; Natera; Novartis; OncoCyte; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; Takeda; Valar Labs; Zola Therapeutics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Lytix Biopharma (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron
 
Jedd Wolchok
Leadership - Ludwig Institute for Cancer Research
Stock and Other Ownership Interests - Apricity Therapeutics; Ascentage Pharma; CellCarta; Georgiamune; Imvaq Therapeutics; Larkspur; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; XenImmune Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; BeiGene; Bicara Therapeutics; Bristol-Myers Squibb; CellCarta; Chugai Pharma; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Immunocore; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Scancell Ltd.; Sellas Life Sciences; Surface Oncology; Takeda; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics; XenImmune Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); ANTIGEN-RECOGNIZING RECEPTORS TARGETING B7-H3 AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
Other Relationship - Immunocore
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); Emory University; OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; IDEAYA Biosciences; immatics; IO Biotech; MSD; Novartis; Obsidian Therapeutics; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; SWOG; TriSalus Life Sciences
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)